Casi Pharmaceuticals (CASI) said Thursday its board received an updated non-binding proposal from Chairman and CEO Wei-Wu He to acquire its entire business operations in China for $20 million.
The proposal includes the acquisition of all of the company's license-in, distribution, and related rights in Asia, excluding Japan, related to certain of its pipeline products. The latest offer updates a preliminary non-binding proposal that He submitted in June 2024, Casi said.
The company's shares were 11.5% higher in premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。